

## BOARD CHANGES

**MELBOURNE (AUSTRALIA) 29 August 2024:** Invion Limited (ASX: IVX) (“**Invion**” or the “**Company**”) is pleased to announce the appointment of Ms Melanie Leydin as a Non-Executive Director, effective 31 August 2024.

Ms Leydin was the Company's former Company Secretary and holds a Bachelor of Business majoring in Accounting and Corporate Law. She is a member of the Institute of Chartered Accountants, Fellow of the Governance Institute of Australia and is a Registered Company Auditor. She graduated from Swinburne University in 1997, became a Chartered Accountant in 1999 and from February 2000 to October 2021 was the principal of Leydin Freyer. In November 2021 Vistra acquired Leydin Freyer and, Melanie is now Vistra Australia's Managing Director.

Vistra is a prominent provider of specialised consulting and administrative services to clients in the Fund, Corporate, Capital Markets, and Private Wealth sectors. Melanie has over 30 years' experience in the accounting profession and over 20 years' experience holding Board positions including Company Secretary of ASX listed entities. She has extensive experience in relation to public company responsibilities, including ASX and ASIC compliance, control and implementation of corporate governance, statutory financial reporting, reorganisation of Companies, initial public offerings, secondary raisings and shareholder relations.

Mr Robert Merriel will resign as Non-Executive Director of Invion, effective 31 August 2024 marking 4 years of service to the Board of Invion Limited. The Board wishes to thank Mr Merriel for his valuable contribution to the Company.

This announcement was approved for release by the Board of Invion Limited.

---

### Investor and Media enquiries:

Thian Chew (Chairman & CEO)

T: +61 3 9692 7222

E: [investor@inviongroup.com](mailto:investor@inviongroup.com)

Brendon Lau (Investor & Media Relations)

M: +61 409 341 613

E: [brendon.lau@inviongroup.com](mailto:brendon.lau@inviongroup.com)

### About Invion

Invion is a life-science company that is leading the global research and development of the Photosoft™ technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. Invion holds the exclusive Australia and New Zealand license rights and exclusive distribution rights to Hong Kong and the rest of Asia Pacific, excluding China, Macau, Taiwan and Japan, to the Photosoft technology for all cancer indications. It also holds the exclusive rights to the technology in Asia and Oceania, excluding China, Hong Kong, Taiwan, Macau, the Middle East and Russia for atherosclerosis and infectious diseases, and subsequently acquired the rights to the United States, Canada and Hong Kong for infectious diseases.

## **ASX ANNOUNCEMENT**

Research and clinical cancer trials are funded by the technology licensor, RMW Cho Group Limited. Invion is listed on the ASX (ASX: IVX).

### **About Photodynamic Therapy (PDT)**

Invion is developing Photosoft™ technology as a novel next generation Photodynamic Therapy (PDT). PDT uses non-toxic photosensitisers and light to selectively kill cancer cells and promote an anti-cancer immune response. Less invasive than surgery and with minimal side effects, PDT offers an alternative treatment option aimed at achieving complete tumour regression and long-lasting remission. PDT has also demonstrated broad-spectrum activity across multiple infectious diseases, including bacteria, fungi and viruses. Photosoft has the potential to address the global challenge of antibiotic-resistant "superbugs".